Recombinant Staphylokinase
020
Approved small_molecule completed
Quick answer
Recombinant Staphylokinase for ST-segment Elevation Myocardial Infarction (STEMI) is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- ST-segment Elevation Myocardial Infarction (STEMI)
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed